{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:40:01Z","timestamp":1775079601803,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s10147-015-0912-6","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T16:16:19Z","timestamp":1444752979000},"page":"498-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy"],"prefix":"10.1007","volume":"21","author":[{"given":"Futoshi","family":"Iioka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotaka","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Kamoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,13]]},"reference":[{"key":"912_CR1","first-page":"233","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"H Stein","year":"2008","unstructured":"Stein H, Chan JKC, Warnke RA et al (2008) Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 233\u2013237"},{"key":"912_CR2","unstructured":"National Cancer Institute (2014) SEER cancer statistics review 1975\u20132011. http:\/\/seer.cancer.gov\/csr\/1975_2011\/browse_csr.php?sectionSEL=19&pageSEL=sect_19_table.27.html"},{"key":"912_CR3","unstructured":"Ministry of Health, Labour and Welfare (2013) Handbook of health and welfare statistics. http:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/life\/life13\/index.html"},{"key":"912_CR4","unstructured":"Statistics Bureau (2015) Japan statistical yearbook. http:\/\/www.stat.go.jp\/english\/data\/nenkan\/1431-02.htm"},{"key":"912_CR5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"912_CR6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379\u2013391","journal-title":"Lancet Oncol"},{"key":"912_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428194.2011.600486","volume":"53","author":"A Meguro","year":"2012","unstructured":"Meguro A, Ozaki K, Sato K et al (2012) Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70\u00a0years and older. Leuk Lymphoma 53:43\u201349","journal-title":"Leuk Lymphoma"},{"key":"912_CR8","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3109\/10428194.2013.780654","volume":"54","author":"K Aoki","year":"2013","unstructured":"Aoki K, Takahashi T, Tabata S et al (2013) Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 54:2441\u20132447","journal-title":"Leuk Lymphoma"},{"key":"912_CR9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdl034","volume":"17","author":"O Bairey","year":"2006","unstructured":"Bairey O, Benjamini O, Blickstein D et al (2006) Non-Hodgkin\u2019s lymphoma in patients 80\u00a0years of age or older. Ann Oncol 17:928\u2013934","journal-title":"Ann Oncol"},{"key":"912_CR10","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdm563","volume":"19","author":"C Thieblemont","year":"2008","unstructured":"Thieblemont C, Grossoeuvre A, Houot R et al (2008) Non-Hodgkin\u2019s lymphoma in very elderly patients over 80\u00a0years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19:774\u2013779","journal-title":"Ann Oncol"},{"key":"912_CR11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C et al (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80\u00a0years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12:460\u2013468","journal-title":"Lancet Oncol"},{"key":"912_CR12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"MA Shipp","year":"1993","unstructured":"Shipp MA (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 329:987\u2013994","journal-title":"N Engl J Med"},{"key":"912_CR13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"912_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00432-003-0508-9","volume":"130","author":"H Tsurumi","year":"2004","unstructured":"Tsurumi H, Yamada T, Sawada M et al (2004) Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin\u2019s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107\u2013113","journal-title":"J Cancer Res Clin Oncol"},{"key":"912_CR15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244","journal-title":"J Clin Oncol"},{"key":"912_CR16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl 48:452\u2013458","journal-title":"Bone Marrow Transpl"},{"key":"912_CR17","doi-asserted-by":"crossref","unstructured":"Morrison VA, Hamlin P, Soubeyran P et al (2015) Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper. J Geriatr Oncol 6:141\u2013152","DOI":"10.1016\/j.jgo.2014.11.004"},{"key":"912_CR18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2011.09011.x","volume":"157","author":"PA Fields","year":"2012","unstructured":"Fields PA, Linch DC (2012) Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol 157:159\u2013170","journal-title":"Br J Haematol"},{"key":"912_CR19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.critrevonc.2010.02.009","volume":"78","author":"A Gutierrez","year":"2011","unstructured":"Gutierrez A, Mestre F, Perez-Manga G et al (2011) Diffuse large B-cell lymphoma in the older. Crit Rev Oncol Hematol 78:59\u201372","journal-title":"Crit Rev Oncol Hematol"},{"key":"912_CR20","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","volume":"96","author":"S Mareschal","year":"2011","unstructured":"Mareschal S, Lanic H, Ruminy P et al (2011) The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 96:1888\u20131890","journal-title":"Haematologica"},{"key":"912_CR21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW et al (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837\u2013842","journal-title":"Blood"},{"key":"912_CR22","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3109\/10428194.2013.869326","volume":"55","author":"CD Fletcher","year":"2014","unstructured":"Fletcher CD, Kahl BS (2014) Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma 55:2228\u20132240","journal-title":"Leuk Lymphoma"},{"key":"912_CR23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","volume":"87","author":"A Bosly","year":"2008","unstructured":"Bosly A, Bron D, Van Hoof A et al (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277\u2013283","journal-title":"Ann Hematol"},{"key":"912_CR24","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, McBride RB, Eisenberger A et al (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:3159\u20133165","journal-title":"J Clin Oncol"},{"key":"912_CR25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cncr.11861","volume":"100","author":"L Balducci","year":"2004","unstructured":"Balducci L, Repetto L (2004) Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 100:6\u201311","journal-title":"Cancer"},{"key":"912_CR26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1532-5415.2003.51152.x","volume":"51","author":"KE Covinsky","year":"2003","unstructured":"Covinsky KE, Palmer RM, Fortinsky RH et al (2003) Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc 51:451\u2013458","journal-title":"J Am Geriatr Soc"},{"key":"912_CR27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ejca.2005.01.010","volume":"41","author":"DJ Spronsen van","year":"2005","unstructured":"van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE et al (2005) Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 41:1051\u20131057","journal-title":"Eur J Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-015-0912-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-015-0912-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T10:37:41Z","timestamp":1559126261000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-015-0912-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,13]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1007\/s10147-015-0912-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,13]]}}}